Insomnia is a common condition, often defined by difficulty falling asleep or staying asleep for sufficient periods. People who suffer from insomnia often complain of significant impairment in their daytime focus and performance, and ultimately a reduced quality of life. Whilst all of these medications had beneficial effects for the short term relief of insomnia, they carry significant drawbacks including the risk of becoming dependant on the medicine, and risks of side effects such as drowsiness, dizziness and cognitive impairment. Daridorexant (Quviviq®) is a new treatment aimed at helping adults struggling with insomnia. In this article, Dr Daniel Gordon outlines some of the key information about this novel medication.